JANX Shares Gain 19.1% in 3 Months: Here's What You Need to Know
Janux stock climbs 19.1% in three months as pipeline progress, upcoming catalysts and a strong cash position boost investor confidence.
JANX - Janux Therapeutics, Inc.
Price:
--
--
|
CONSENSUS:
Buy
DETAILS
|
PRICE TARGET:
$29.00
DETAILS
HIGH:
$55.00
LOW:
$14.00
MEDIAN:
$26.00
CONSENSUS:
$29.00
UPSIDE:
66.76%
Stock News
Janux Therapeutics, Inc. (JANX) Reports Q2 Loss, Lags Revenue Estimates
Janux Therapeutics, Inc. (JANX) came out with a quarterly loss of $0.35 per share versus the Zacks Consensus Estimate of a loss of $0.26. This compares to a loss of $0.55 per share a year ago.
Janux Therapeutics Reports Second Quarter 2026 Financial Results and Business Highlights
SAN DIEGO--(BUSINESS WIRE)--Janux Therapeutics, Inc. (Nasdaq: JANX) (Janux), a clinical-stage biopharmaceutical company developing a broad pipeline of novel immunotherapies, today reported financial results for the quarter ended June 30, 2026, and provided a business update. "During the second quarter we continued to execute across our clinical portfolio while preparing for multiple upcoming milestones," said David Campbell, Ph.D., President and Chief Executive Officer of Janux. "Enrollment con.
Wall Street Analysts Predict a 155.82% Upside in Janux Therapeutics (JANX): Here's What You Should Know
The mean of analysts' price targets for Janux Therapeutics (JANX) points to a 155.8% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.
Here's Why You Should Add JANX Stock to Your Portfolio Now
Janux Therapeutics advances multiple oncology and immune therapy programs with key clinical updates, new studies and expanded partnerships with BMY and MRK.
Janux Therapeutics, Inc. (JANX) Reports Q1 Loss, Lags Revenue Estimates
Janux Therapeutics, Inc. (JANX) came out with a quarterly loss of $0.39 per share versus the Zacks Consensus Estimate of a loss of $0.5. This compares to a loss of $0.38 per share a year ago.
Janux Therapeutics Reports First Quarter 2026 Financial Results and Business Highlights
SAN DIEGO--(BUSINESS WIRE)--Janux Therapeutics, Inc. (Nasdaq: JANX) (Janux), a clinical-stage biopharmaceutical company developing a broad pipeline of novel immunotherapies, today reported financial results for the quarter ended March 31, 2026, and provided a business update. "Our commitment to advancing a prostate cancer franchise is demonstrated by our continued progress with JANX007, clinical initiation of JANX014, and advancement of JANX013 toward the clinic,” said David Campbell, Ph.D., Pr.
How Much Upside is Left in Janux Therapeutics (JANX)? Wall Street Analysts Think 180.44%
The consensus price target hints at an 180.4% upside potential for Janux Therapeutics (JANX). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.
Janux Therapeutics: Strong Buy As Pipeline Advances, Stock Trades Below Cash Value
Janux Therapeutics, Inc. is upgraded to Strong Buy, trading below cash value with a robust cash runway and validated technology platforms. Discontinuation of JANX008 demonstrates financial discipline, reallocating resources to higher-potential assets and further validating the TRACTr platform. Strategic partnerships with Merck and BMY could yield up to $1.8 billion in milestones plus royalties, supporting long-term value creation.
Janux Therapeutics Announces Discontinuation of JANX008 Clinical Development
SAN DIEGO--(BUSINESS WIRE)--Janux Therapeutics, Inc. (Nasdaq: JANX) (“Janux”), a clinical-stage biopharmaceutical company developing a broad pipeline of novel immunotherapies, today announced that it will discontinue further clinical development of JANX008, its EGFR-targeted Tumor Activated T Cell Engager (TRACTr) program. Following completion of the Phase 1a portion of the study, which included dose escalation and expansion cohorts across multiple solid tumor indications, and an internal revie.
Janux Therapeutics Announces First Participant Dosed in Phase 1 Study of JANX014
SAN DIEGO--(BUSINESS WIRE)--Janux Therapeutics, Inc. (Nasdaq: JANX) (Janux), a clinical-stage biopharmaceutical company developing a broad pipeline of novel immunotherapies, today announced that the first patient has been dosed in a Phase 1 clinical trial of JANX014 in patients with metastatic castration-resistant prostate cancer (mCRPC). JANX014 is a double-masked, prostate-specific membrane antigen (PSMA) directed T cell engager (TCE) designed to leverage Janux's tumor-activated technology pl.
Janux Therapeutics Secures $35M Milestone Payment From BMY Deal
JANX earns $35M milestone payment from Bristol Myers as TRACTr-based cancer candidate advances, signaling progress in its tumor-activated therapy platform.
Janux Therapeutics Announces Development Candidate Nomination Under Bristol Myers Squibb Collaboration, Triggering $35 Million Milestone Payment
SAN DIEGO--(BUSINESS WIRE)--Janux Therapeutics, Inc. (Nasdaq: JANX) (Janux), a clinical-stage biopharmaceutical company developing a broad pipeline of novel immunotherapies, today announced the nomination of a development candidate under its collaboration and exclusive worldwide license agreement with Bristol Myers Squibb. The milestone was achieved following the identification of a tumor-activated therapeutic, utilizing Janux's TRACTr platform, targeting an undisclosed solid tumor antigen expr.
Janux Therapeutics, Inc. (NASDAQ:JANX) Receives Consensus Recommendation of “Moderate Buy” from Analysts
Shares of Janux Therapeutics, Inc. (NASDAQ: JANX - Get Free Report) have been assigned an average rating of "Moderate Buy" from the fourteen ratings firms that are currently covering the stock, Marketbeat.com reports. One equities research analyst has rated the stock with a sell rating, two have issued a hold rating and eleven have given a
Janux Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Business Highlights
SAN DIEGO--(BUSINESS WIRE)--Janux Therapeutics, Inc. (Nasdaq: JANX) (Janux), a clinical-stage biopharmaceutical company developing a broad pipeline of novel immunotherapies, today reported financial results for the fourth quarter and full year ended December 31, 2025, and provided a business update. “The past year marked a period of significant execution and progress for Janux as we continued to translate the promise of our tumor-activated platform into meaningful clinical and strategic advance.
Janux Therapeutics Announces First Patient Dosed in Phase 1 Study of JANX011
SAN DIEGO--(BUSINESS WIRE)--Janux Therapeutics Announces First Patient Dosed in Phase 1 Study of JANX011.
Wall Street Thinks These 4 Biotech Stocks Will Double–At Least–This Year
Wall Street analysts are placing aggressive bets on four clinical-stage biotech companies, with consensus price targets implying gains of up to 384%.
Wall Street Analysts See a 319.23% Upside in Janux Therapeutics (JANX): Can the Stock Really Move This High?
The average of price targets set by Wall Street analysts indicates a potential upside of 319.2% in Janux Therapeutics (JANX). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.
Janux Therapeutics Appoints William Go, M.D., Ph.D., as Chief Medical Officer
SAN DIEGO--(BUSINESS WIRE)--Janux Therapeutics, Inc., a clinical-stage biopharmaceutical company developing a broad pipeline of novel immunotherapies based on its proprietary Tumor Activated T Cell Engager (TRACTr), Tumor Activated Immunomodulator (TRACIr), and Adaptive Immune Response Modulator (ARM) platforms, today announced that William Go, M.D., Ph.D., has been appointed Chief Medical Officer, effective January 26, 2026. Dr. Go succeeds Zachariah McIver, D.O., Ph.D., who will be leaving th.
JANX Enters Global Oncology Collaboration With BMY, Stock Rises
Janux Therapeutics struck a global licensing deal for its tumor-activated platforms, sending shares higher and expanding its reach in solid tumors.
Price Targets
Janux Therapeutics price target lowered to $35 from $38 at Stifel
$35.00
(was $16.00)
Stifel Nicolaus
Janux Therapeutics price target lowered to $55 from $58 at Guggenheim
$55.00
(was $16.10)
Guggenheim
Janux Therapeutics assumed with a Buy at Truist
$26.00
(was $14.64)
Truist Financial
Janux Therapeutics price target lowered to $22 from $23 at Evercore ISI
$22.00
(was $14.40)
Evercore ISI
Janux Therapeutics price target lowered to $36 from $45 at Wedbush
$36.00
(was $14.33)
Wedbush
Janux Therapeutics downgraded to Underweight from Overweight at Barclays
$14.00
(was $15.82)
Etzer Darout
·
Barclays
Janux Therapeutics downgraded to Neutral from Buy at UBS
$15.00
(was $15.24)
UBS
Janux Therapeutics price target lowered to $30 from $42 at Piper Sandler
$30.00
(was $13.72)
Kelsey Goodwin
·
Piper Sandler
Janux Therapeutics price target lowered to $29 from $48 at Barclays
$29.00
(was $14.65)
Barclays
Janux Therapeutics (JANX) Reiterated at Buy by UBS After JANX007 Ph1 update
$57.00
(was $17.28)
David Dai
·
UBS
Janux Therapeutics price target lowered to $38 from $46 at Stifel
$38.00
(was $33.99)
Stephen Willey
·
Stifel Nicolaus
Janux Therapeutics price target lowered to $45 from $70 at H.C. Wainwright
$45.00
(was $33.99)
H.C. Wainwright
Janux Therapeutics initiated with an Overweight at Barclays
$47.00
(was $23.41)
Barclays
Janux Therapeutics resumed with a Buy at Stifel
$45.00
(was $24.31)
Stifel Nicolaus
Janux Therapeutics initiated with a Buy at Guggenheim
$72.00
(was $23.04)
Brad Canino
·
Guggenheim
Janux Therapeutics initiated with an Outperform at Raymond James
$65.00
(was $25.15)
Sean McCutcheon
·
Raymond James
Janux Therapeutics price target lowered to $41 from $62 at Scotiabank
$41.00
(was $32.89)
Scotiabank
Janux Therapeutics price target raised to $76 from $75 at Wedbush
$76.00
(was $32.89)
Wedbush
Janux Therapeutics (JANX) PT Raised to $100 at BTIG, 'The World Is Not Enough — 007 Strikes Again Exceeding The Street's Highest Expectations'
$100.00
(was $40.18)
Justin Zelin
·
BTIG
UBS Starts Janux Therapeutics (JANX) at Buy
$69.00
(was $51.75)
David Dai
·
UBS